Eversept Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Eversept Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-78,987	Closed	-$11.5M	–	71
2022 Q2	$11.5M	Buy	78,987 +26,116	+49%	+$3.7M	0.82%	35
2022 Q1	$8.63M	Sell	52,871 -17,369	-25%	-$2.65M	0.66%	40
2021 Q4	$11.9M	Buy	70,240 +11,007	+19%	+$2.05M	0.76%	37
2021 Q3	$11.2M	Buy	59,233 +8,097	+16%	+$1.52M	0.77%	37
2021 Q2	$8.67M	Sell	51,136 -29,801	-37%	-$4.36M	0.58%	39
2021 Q1	$11.4M	Buy	+80,937	New	+$12.2M	0.86%	32
2019 Q4	–	Sell	-92,040	Closed	-$7.4M	–	73
2019 Q3	$7.4M	Buy	92,040 +4,900	+6%	+$388K	2.3%	12
2019 Q2	$6.32M	Buy	+87,140	New	+$6.69M	1.77%	16
2018 Q3	–	Sell	-63,493	Closed	-$6.25M	–	65
2018 Q2	$6.25M	Sell	63,493 -15,400	-20%	-$1.53M	2.86%	12
2018 Q1	$9.4M	Buy	+78,893	New	+$10.2M	4.36%	8

Other funds holding ALNY

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Eversept Partners's ALNY Position: Q3 2022 in Review

Eversept Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2022, closing a stake of 78,987 shares — an estimated $11.5M sold.

Eversept Partners first reported a position in ALNY in Q1 2018 and held it in 10 quarters. The position peaked at $11.9M in Q4 2021. 497 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

Eversept Partners reported no remaining Alnylam Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Eversept Partners sold 78,987 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $11.5M.
Eversept Partners first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 10 quarters.
Eversept Partners's Alnylam Pharmaceuticals position peaked at $11.9M in Q4 2021.
497 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.